Developer docs
API playgroundTry for free, no card

Search company profiles

Evia Bio

Full company profile

uuid0002jr4

Namestring
Evia Bio
Legal namestring
Evia Bio
Websiteurl
eviabio.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Evia Bio is a Minneapolis-based life sciences company developing DMSO-free cryopreservation solutions for the cell and gene therapy market. Its core technology is an osmolyte-based cryoprotectant system using naturally-occurring sugars, sugar alcohols, and amino acids, paired with a proprietary algorithm that customizes formulations to specific cell types (MSCs, iPSCs, T-cells, sensory neurons, and heterogeneous populations such as leukopaks). The technology was developed over 30 years of research by founder and CSO Allison Hubel, PhD, a world-renowned cryobiologist, MIT-trained engineer, President of the Society for Cryobiology, and Professor at the University of Minnesota.

The company's commercial offering centers on the CellShield product line—anchored by the CellShield MSC Cryo Kit launched in November 2025 at $475-$550 per 100mL RUO kit, with GMP grade planned for Q1 2026—and a suite of cryo-engineering services: CryoGAP (risk assessment), CryoConsulting (biweekly advisory), and CryoCustom Development (custom formulation and protocol development). Manufacturing is outsourced to Teknova, enabling scale-up without internal GMP capacity. Evia Bio sells direct through its e-commerce site and an enterprise sales motion, targeting MSC-based cell therapy developers, broader cell therapy developers (T, B, NK, PBMC, HSC, iPSC-derived), CDMOs, and the IVF industry.

The company operates from a ~8-10 person team, closed a seed round in Q2 2023, and is led by Chairman & CEO Jeffrey Allen (formerly CEO of Cellero, sold to Charles River Labs) following a May 2024 leadership transition. A multi-channel educational program—CryoChats roundtables, CryoU webinars, CryoX hands-on training, and CryoToons comics—functions as community-led demand generation in a niche where buyer education on DMSO toxicity is the primary adoption barrier. Third-party validation comes from the PACT/BEST Collaborative Study across seven cell therapy laboratories and testing at an unnamed leading CDMO.

Short descriptiontext

Evia Bio is a Minneapolis-based life sciences company that sells DMSO-free cryopreservation kits and consulting services—anchored by its osmolyte-based CellShield platform—to MSC and broader cell therapy developers, CDMOs, and the IVF industry.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMinneapolis, United States
HQ citystring
Minneapolis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
non-DMSO cryopreservation, cell therapy cryopreservation, osmolyte-based preservation, MSC cryopreservation kits, cryobiology consulting services
Industry2 codes
PRIMARYHLAAAJAN
Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAGAIAJ
Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Cell Therapy Cryopreservation Reagents
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1CellShield Product Sales
TypeOne Time License
Description

Sale of CellShield MSC cryopreservation kits, including RUO grade currently available and GMP grade planned for Q1 2026. The 100mL kit includes 2X CPA solution, buffer, and optimized protocol.

eviabio.com
2CryoGAP Risk Assessment Services
TypeProfessional Services
Description

Consulting service providing assessment of gaps and risk factors across the entire cryopreservation process including preparation, freezing, storage/transportation, and thawing/post-thaw assessment.

eviabio.com
3CryoConsulting Services
TypeProfessional Services
Description

Biweekly consulting engagement with Evia Bio team to improve and refine cryopreservation processes.

eviabio.com
4CryoCustom Development Services
TypeProfessional Services
Description

Comprehensive customization service for cell-specific requirements including formulation development, cryopreservation protocol development, and temperature/load mapping for scale up and technology transfer.

eviabio.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations
Pricing details2 tiers
1CellShield MSC RUO Grade 100mL Kit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$475 per 100mL kit (from product page). The kit includes CellShield MSC 2X CPA, CellShield MSC Buffer, and CellShield MSC Cryopreservation Protocol.

eviabio.com
2CellShield MSC RUO Grade 100mL Kit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$550 per 100mL kit (from press release). GMP grade expected by end of Q1 2026.

biospace.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 9 records shown
1CryoGAP
Description

Risk assessment and audit service for cryopreservation protocols

eviabio.com
+8 more records
Core offering1 text field

Evia Bio develops and sells DMSO-free cryopreservation kits (CellShield MSC) using proprietary osmolyte-based technology for cell therapy developers. The company also provides cryopreservation risk assessment (CryoGAP), biweekly consulting (CryoConsulting), and custom formulation/protocol development services (CryoCustom Development) for cell therapy manufacturers and CDMOs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • >85% recovery and viability with iPSCs, MSCs, sensory neurons, and T-cells
+3 more records
Product overview1 text field

Evia Bio is a life science innovation company providing non-DMSO cryopreservation solutions for the cell therapy and in vitro fertilization industries. The core product offering is the CellShield platform—a DMSO-free cryopreservation system using osmolyte-based technology (sugars, sugar alcohols, amino acids) inspired by nature. The CellShield MSC Cryo Kit is their first proprietary product for mesenchymal stem cells. The company also offers a suite of cryo-engineering services including CryoGAP (risk assessment), CryoConsulting (ongoing advisory), and CryoCustom Development (custom formulation services). Educational offerings include CryoU webinars, CryoChats roundtables, CryoX hands-on training, CryoToons educational comics, and CryoTip technical guides. All solutions are developed by world-leading cryobiologist Allison Hubel, PhD, from the University of Minnesota.

Product and service4 records
1CellShield MSC Cryo Kit
CategoryCell therapy cryopreservation reagents
Description

A DMSO-free, fully defined, protein-free cryopreservation kit for mesenchymal stem cells (MSCs) using proprietary osmolyte technology combining penetrating and non-penetrating cryoprotectants (sugars, sugar alcohols, amino acids). Kit includes 2X CPA solution, buffer, and optimized controlled rate freezing protocol. Designed for MSC-based cell therapy developers needing to eliminate DMSO toxicity while maintaining cell integrity.

2CryoGAP Risk Assessment
CategoryCryopreservation consulting services
Description

Cryopreservation risk assessment service that evaluates gaps and risk factors across the entire cryopreservation process, including preparation and formulation, freezing, storage and transportation, and thawing and post-thaw assessment. Offered as Complete (full assessment), Select (individual categories), Risk Mitigation (action plan), and Annual Audit. Designed for cell therapy developers and CDMOs needing validated, GMP-ready cryopreservation processes.

3CryoConsulting
CategoryCryopreservation consulting services
Description

Biweekly consulting engagement with the Evia Bio team to improve and refine cryopreservation processes. Targeted at cell therapy developers, CDMOs, and manufacturers seeking ongoing expert support for protocol optimization and process improvement.

4CryoCustom Development
CategoryCryopreservation custom development services
Description

Custom formulation development service for cell-specific cryopreservation requirements, including cryopreservation protocol development and extensive temperature and load mapping for scale up and technology transfer. Designed for cell therapy developers working with unique cell populations (T-cells, iPSCs, NK cells, MSCs, leukopaks) needing tailored cryoprotectant formulations.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-11-12
Description

Teknova manufactures CellShield MSC as a leading provider of critical reagents for development and commercialization of emerging therapies, vaccines, and molecular diagnostics. This manufacturing partnership enables Evia Bio to scale production while leveraging Teknova's expertise in critical reagent manufacturing.

2PACT/BEST Collaborative Study (7 Cell Therapy Laboratories)
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Multi-center international study involving seven cell therapy laboratories that validated CellShield MSC delivered viability and recovery comparable to DMSO-based standards while maintaining identical cell surface phenotypes (CD45, CD73, CD90, CD105). This validation provides third-party credibility for the product.

eviabio.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with University of Minnesota's Biopreservation Core Resource (BioCoR) for hosting the Preservation of Cellular Therapies Short Course. Founder Allison Hubel serves as Director of BioCoR, creating natural collaboration between academic research and commercial applications.

4Technological Leadership Institute, University of Minnesota
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-hosts the Preservation of Cellular Therapies Short Course with Evia Bio's CryoX Add-On Laboratory Training. Allison Hubel serves as Director of the Technological Leadership Institute at the University of Minnesota.

eviabio.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Cryoport is listed as an institutional supporter for CryoX training. Dominic Clarke, VP Technical Operations at IntegriCell for Cryoport Systems, serves on Evia Bio's Scientific Advisory Board.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

BioLife Solutions is the leading independent supplier of biopreservation products for cell and gene therapies, including the CryoStor and HypoThermosol DMSO-free cryopreservation media lines. It is the most direct competitor to Evia Bio's CellShield platform, serving the same MSC, iPSC, and immune cell therapy developers with established regulatory filings and global distribution.

TypeDirect peer
Description

STEMCELL Technologies sells a broad portfolio of cell culture media, cryopreservation reagents (e.g., CryoStor-style DMSO-free media), and tools for cell therapy and regenerative medicine research. It is a direct competitor to Evia Bio in supplying MSC and immune cell cryopreservation consumables to academic and translational customers.

3Corning Life Sciences
TypeDirect peer
Description

Corning offers defined, serum-free and DMSO-free cryopreservation media (e.g., Cryopreserve DMSO-Free) alongside cell culture vessels and bioprocessing consumables. It competes with Evia Bio across the same cell therapy developer customer base, leveraging an entrenched catalog and global commercial reach.

TypeDirect peer
Description

FUJIFILM Irvine Scientific provides cell culture media and cryopreservation solutions for cell therapy, regenerative medicine, and IVF applications. Its product breadth and IVF adjacency overlap directly with Evia Bio's stated cell therapy and IVF customer segments.

TypeBroad incumbent
Description

Sartorius is a major bioprocessing supplier offering cell culture media, single-use technologies, and cell therapy manufacturing platforms. Through its bioprocessing catalog it competes broadly with Evia Bio for cell therapy developer wallet share, even though cryopreservation media is not its primary focus.

TypeBroad incumbent
Description

Lonza is a global CDMO and supplier of cell and gene therapy manufacturing services, including media and process development. Its cell therapy manufacturing platform and media offerings overlap with Evia Bio's CDMO customer segment and broader cryopreservation/process tooling value proposition.

TypeBroad incumbent
Description

Cytiva (formerly part of GE Healthcare Life Sciences) supplies bioprocessing tools, cell culture media, and cryopreservation solutions for cell and gene therapy developers. It competes with Evia Bio as part of a much broader bioprocessing portfolio targeting CDMOs and therapy developers.

8MilliporeSigma
TypeBroad incumbent
Description

MilliporeSigma (the life science business of Merck KGaA) provides an extensive catalog of cell culture media, cryoprotectants, and bioprocessing consumables. It overlaps with Evia Bio across research-grade and clinical-grade cryopreservation reagents, sold through a global life sciences sales channel.

TypeEmerging player
Description

Pluristyx is an emerging iPSC-focused cell therapy tools and services company offering GMP-grade iPSC lines and related manufacturing support. It intersects with Evia Bio in the iPSC cryopreservation workflow, and the company's CEO previously served as a Strategic Advisor to Pluristyx.

TypeOthers
Description

Cryoport is a specialty logistics and cold-chain provider for cell and gene therapies, offering cryogenic shipping and chain-of-custody services. It is an enabling/adjacent ecosystem partner rather than a direct reagent competitor; Cryoport's VP of Technical Operations for IntegriCell also serves on Evia Bio's Scientific Advisory Board.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Evia Bio

Cell Therapy Cryopreservation Reagentseviabio.com

Evia Bio is a Minneapolis-based life sciences company that sells DMSO-free cryopreservation kits and consulting services—anchored by its osmolyte-based CellShield platform—to MSC and broader cell therapy developers, CDMOs, and the IVF industry.

What Evia Bio does

Evia Bio is a Minneapolis-based life sciences company developing DMSO-free cryopreservation solutions for the cell and gene therapy market. Its core technology is an osmolyte-based cryoprotectant system using naturally-occurring sugars, sugar alcohols, and amino acids, paired with a proprietary algorithm that customizes formulations to specific cell types (MSCs, iPSCs, T-cells, sensory neurons, and heterogeneous populations such as leukopaks). The technology was developed over 30 years of research by founder and CSO Allison Hubel, PhD, a world-renowned cryobiologist, MIT-trained engineer, President of the Society for Cryobiology, and Professor at the University of Minnesota.

The company's commercial offering centers on the CellShield product line—anchored by the CellShield MSC Cryo Kit launched in November 2025 at $475-$550 per 100mL RUO kit, with GMP grade planned for Q1 2026—and a suite of cryo-engineering services: CryoGAP (risk assessment), CryoConsulting (biweekly advisory), and CryoCustom Development (custom formulation and protocol development). Manufacturing is outsourced to Teknova, enabling scale-up without internal GMP capacity. Evia Bio sells direct through its e-commerce site and an enterprise sales motion, targeting MSC-based cell therapy developers, broader cell therapy developers (T, B, NK, PBMC, HSC, iPSC-derived), CDMOs, and the IVF industry.

The company operates from a ~8-10 person team, closed a seed round in Q2 2023, and is led by Chairman & CEO Jeffrey Allen (formerly CEO of Cellero, sold to Charles River Labs) following a May 2024 leadership transition. A multi-channel educational program—CryoChats roundtables, CryoU webinars, CryoX hands-on training, and CryoToons comics—functions as community-led demand generation in a niche where buyer education on DMSO toxicity is the primary adoption barrier. Third-party validation comes from the PACT/BEST Collaborative Study across seven cell therapy laboratories and testing at an unnamed leading CDMO.

Evia Bio firmographics

Firmographics
Name
Evia Bio
Legal name
Evia Bio
Website
https://eviabio.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Evia Bio is a Minneapolis-based life sciences company that sells DMSO-free cryopreservation kits and consulting services—anchored by its osmolyte-based CellShield platform—to MSC and broader cell therapy developers, CDMOs, and the IVF industry.
Ownership category
akta.pro rank

Evia Bio industry classification

Industry
Product category
Cell Therapy Cryopreservation Reagents
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAJAN
Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAGAIAJ
Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats)

Keywords

  • Non-DMSO cryopreservation
  • Cell therapy cryopreservation
  • Osmolyte-based preservation
  • MSC cryopreservation kits
  • Cryobiology consulting services

Where Evia Bio is headquartered

Location

Headquarters

HQ city
Minneapolis
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Evia Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. CellShield Product Sales: Sale of CellShield MSC cryopreservation kits, including RUO grade currently available and GMP grade planned for Q1 2026. The 100mL kit includes 2X CPA solution, buffer, and optimized protocol.
  2. CryoGAP Risk Assessment Services: Consulting service providing assessment of gaps and risk factors across the entire cryopreservation process including preparation, freezing, storage/transportation, and thawing/post-thaw assessment.
  3. CryoConsulting Services: Biweekly consulting engagement with Evia Bio team to improve and refine cryopreservation processes.
  4. CryoCustom Development Services: Comprehensive customization service for cell-specific requirements including formulation development, cryopreservation protocol development, and temperature/load mapping for scale up and technology transfer.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goCellShield MSC RUO Grade 100mL Kit
Unit PricingPay-as-you-goCellShield MSC RUO Grade 100mL Kit

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Evia Bio product offering

Product offering

Core offering

Evia Bio develops and sells DMSO-free cryopreservation kits (CellShield MSC) using proprietary osmolyte-based technology for cell therapy developers. The company also provides cryopreservation risk assessment (CryoGAP), biweekly consulting (CryoConsulting), and custom formulation/protocol development services (CryoCustom Development) for cell therapy manufacturers and CDMOs.

Product overview

Evia Bio is a life science innovation company providing non-DMSO cryopreservation solutions for the cell therapy and in vitro fertilization industries. The core product offering is the CellShield platform—a DMSO-free cryopreservation system using osmolyte-based technology (sugars, sugar alcohols, amino acids) inspired by nature. The CellShield MSC Cryo Kit is their first proprietary product for mesenchymal stem cells. The company also offers a suite of cryo-engineering services including CryoGAP (risk assessment), CryoConsulting (ongoing advisory), and CryoCustom Development (custom formulation services). Educational offerings include CryoU webinars, CryoChats roundtables, CryoX hands-on training, CryoToons educational comics, and CryoTip technical guides. All solutions are developed by world-leading cryobiologist Allison Hubel, PhD, from the University of Minnesota.

Differentiator

Problem solved

Functional benefit

Brands

  • CryoGAP: Risk assessment and audit service for cryopreservation protocols
  • CryoConsulting
  • CryoCustom Development
  • CellShield
  • CryoU
  • CryoChats
  • CryoX
  • CryoToons
  • CryoTip

Products and services

  • CellShield MSC Cryo Kit A DMSO-free, fully defined, protein-free cryopreservation kit for mesenchymal stem cells (MSCs) using proprietary osmolyte technology combining penetrating and non-penetrating cryoprotectants (sugars, sugar alcohols, amino acids). Kit includes 2X CPA solution, buffer, and optimized controlled rate freezing protocol. Designed for MSC-based cell therapy developers needing to eliminate DMSO toxicity while maintaining cell integrity.
  • CryoGAP Risk Assessment Cryopreservation risk assessment service that evaluates gaps and risk factors across the entire cryopreservation process, including preparation and formulation, freezing, storage and transportation, and thawing and post-thaw assessment. Offered as Complete (full assessment), Select (individual categories), Risk Mitigation (action plan), and Annual Audit. Designed for cell therapy developers and CDMOs needing validated, GMP-ready cryopreservation processes.
  • CryoConsulting Biweekly consulting engagement with the Evia Bio team to improve and refine cryopreservation processes. Targeted at cell therapy developers, CDMOs, and manufacturers seeking ongoing expert support for protocol optimization and process improvement.
  • CryoCustom Development Custom formulation development service for cell-specific cryopreservation requirements, including cryopreservation protocol development and extensive temperature and load mapping for scale up and technology transfer. Designed for cell therapy developers working with unique cell populations (T-cells, iPSCs, NK cells, MSCs, leukopaks) needing tailored cryoprotectant formulations.

Quantifiable outcome

  • >85% recovery and viability with iPSCs, MSCs, sensory neurons, and T-cells
  • +3 more outcomes

Companies that use Evia Bio

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Evia Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Evia Bio partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core, flagship and minor.

  • TeknovacoreOEM/ Whitelabel/ Licensing Partner · 12 November 2025Teknova manufactures CellShield MSC as a leading provider of critical reagents for development and commercialization of emerging therapies, vaccines, and molecular diagnostics. This manufacturing partnership enables Evia Bio to scale production while leveraging Teknova's expertise in critical reagent manufacturing.
  • PACT/BEST Collaborative Study (7 Cell Therapy Laboratories)flagshipStrategic or Co-development PartnerMulti-center international study involving seven cell therapy laboratories that validated CellShield MSC delivered viability and recovery comparable to DMSO-based standards while maintaining identical cell surface phenotypes (CD45, CD73, CD90, CD105). This validation provides third-party credibility for the product.
  • University of Minnesota - BioCoRcoreStrategic or Co-development PartnerPartnership with University of Minnesota's Biopreservation Core Resource (BioCoR) for hosting the Preservation of Cellular Therapies Short Course. Founder Allison Hubel serves as Director of BioCoR, creating natural collaboration between academic research and commercial applications.
  • Technological Leadership Institute, University of MinnesotacoreStrategic or Co-development PartnerCo-hosts the Preservation of Cellular Therapies Short Course with Evia Bio's CryoX Add-On Laboratory Training. Allison Hubel serves as Director of the Technological Leadership Institute at the University of Minnesota.
  • CryoportminorGTM or Marketing PartnerCryoport is listed as an institutional supporter for CryoX training. Dominic Clarke, VP Technical Operations at IntegriCell for Cryoport Systems, serves on Evia Bio's Scientific Advisory Board.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Evia Bio competitors and assessment

Company assessment

Direct peers

  • BioLife Solutions: BioLife Solutions is the leading independent supplier of biopreservation products for cell and gene therapies, including the CryoStor and HypoThermosol DMSO-free cryopreservation media lines. It is the most direct competitor to Evia Bio's CellShield platform, serving the same MSC, iPSC, and immune cell therapy developers with established regulatory filings and global distribution.
  • STEMCELL Technologies: STEMCELL Technologies sells a broad portfolio of cell culture media, cryopreservation reagents (e.g., CryoStor-style DMSO-free media), and tools for cell therapy and regenerative medicine research. It is a direct competitor to Evia Bio in supplying MSC and immune cell cryopreservation consumables to academic and translational customers.
  • Corning Life Sciences: Corning offers defined, serum-free and DMSO-free cryopreservation media (e.g., Cryopreserve DMSO-Free) alongside cell culture vessels and bioprocessing consumables. It competes with Evia Bio across the same cell therapy developer customer base, leveraging an entrenched catalog and global commercial reach.
  • FUJIFILM Irvine Scientific: FUJIFILM Irvine Scientific provides cell culture media and cryopreservation solutions for cell therapy, regenerative medicine, and IVF applications. Its product breadth and IVF adjacency overlap directly with Evia Bio's stated cell therapy and IVF customer segments.

Broad incumbents

  • Sartorius: Sartorius is a major bioprocessing supplier offering cell culture media, single-use technologies, and cell therapy manufacturing platforms. Through its bioprocessing catalog it competes broadly with Evia Bio for cell therapy developer wallet share, even though cryopreservation media is not its primary focus.
  • Lonza: Lonza is a global CDMO and supplier of cell and gene therapy manufacturing services, including media and process development. Its cell therapy manufacturing platform and media offerings overlap with Evia Bio's CDMO customer segment and broader cryopreservation/process tooling value proposition.
  • Cytiva: Cytiva (formerly part of GE Healthcare Life Sciences) supplies bioprocessing tools, cell culture media, and cryopreservation solutions for cell and gene therapy developers. It competes with Evia Bio as part of a much broader bioprocessing portfolio targeting CDMOs and therapy developers.
  • MilliporeSigma: MilliporeSigma (the life science business of Merck KGaA) provides an extensive catalog of cell culture media, cryoprotectants, and bioprocessing consumables. It overlaps with Evia Bio across research-grade and clinical-grade cryopreservation reagents, sold through a global life sciences sales channel.

Emerging players

  • Pluristyx: Pluristyx is an emerging iPSC-focused cell therapy tools and services company offering GMP-grade iPSC lines and related manufacturing support. It intersects with Evia Bio in the iPSC cryopreservation workflow, and the company's CEO previously served as a Strategic Advisor to Pluristyx.

Others

  • Cryoport Systems: Cryoport is a specialty logistics and cold-chain provider for cell and gene therapies, offering cryogenic shipping and chain-of-custody services. It is an enabling/adjacent ecosystem partner rather than a direct reagent competitor; Cryoport's VP of Technical Operations for IntegriCell also serves on Evia Bio's Scientific Advisory Board.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Evia Bio social profiles

Digital presence

Evia Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Evia Bio leadership team

Management profile

Number of profiles

Profiles9 records

Evia Bio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Evia Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evia Bio

What does Evia Bio do?

Evia Bio develops and sells DMSO-free cryopreservation kits (CellShield MSC) using proprietary osmolyte-based technology for cell therapy developers. The company also provides cryopreservation risk assessment (CryoGAP), biweekly consulting (CryoConsulting), and custom formulation/protocol development services (CryoCustom Development) for cell therapy manufacturers and CDMOs.

Is Evia Bio a public or private company?

Evia Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Evia Bio founded?

Evia Bio was founded in 2020. It employs 1 to 10 people.

Where is Evia Bio based?

Evia Bio is headquartered in Minneapolis, United States, in the North America region.

How does Evia Bio make money?

Four revenue lines are on record. CellShield Product Sales are the primary driver. The others are cryoGAP Risk Assessment Services, cryoConsulting Services and cryoCustom Development Services.

Who are Evia Bio's main competitors?

Direct peers on record are BioLife Solutions, STEMCELL Technologies, Corning Life Sciences and FUJIFILM Irvine Scientific. Broad incumbents are Sartorius, Lonza, Cytiva and MilliporeSigma. Pluristyx is listed as an emerging player. Cryoport Systems is listed as an others.

Does Evia Bio have an API?

No public API is recorded for Evia Bio.

What industry is Evia Bio in?

Evia Bio's product category is Cell Therapy Cryopreservation Reagents. Its primary akta.pro industry code is HLAAAJAN, Cold Chain, Cryopreservation & Biologics Storage/Handling Technologies, with a secondary code of HLAGAIAJ, Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceEvia Bio Closes Series A Financing to Accelerate Growth of DMSO-Free Cryopreservation SolutionsEvia Bio closed its Series A financing round to support product development and commercial expansion. The company launched its first DMSO-free cryo media for MSCs in Q4 2025 and will introduce additional products for T cells and CAR-T therapies over the next six to nine months.BioSpaceEvia Bio® Introduces CellShieldTM MSC DMSO-Free Cryopreservation Media KitEvia Bio announced the launch of CellShield MSC, a DMSO-free cryopreservation media kit specifically designed for MSC-based cell therapy developers, representing their first proprietary cryopreservation solution. The product, manufactured by Teknova, claims to deliver equivalent or better performance compared to traditional DMSO-based solutions while eliminating toxic effects, with RUO grade available now at $550 per 100 mL kit and GMP grade expected by the end of Q1 2026.PR NewswireCellipont Bioservices and Evia Bio Collaborate to Launch Cryo Excellence Center (CryoX) in Houston, TXCellipont Bioservices and Evia Bio announced a strategic partnership to launch the Cryopreservation Excellence Center (CryoX) at Cellipont's cGMP cell therapy manufacturing facilities in The Woodlands, TX, with operations beginning in 2024. The center, led by world-renowned cryobiologist Allison Hubel, will provide training and advance cryopreservation techniques for cell therapies to enable safer global supply chains. The launch coincides with Cellipont's opening of a new 76,000 sq. ft. cGMP manufacturing facility scheduled for February 2024.PR NewswireBlueCube Bio becomes Evia Bio™ and launches new IPSC cryopreservation solution to accelerate cell & gene therapiesBlueCube Bio announced a company name transition to Evia Bio™ alongside the launch of a new DMSO-free cryopreservation solution for induced pluripotent stem cells used in cell and gene therapies. The osmolyte-based solution demonstrated superior post-thaw cell viability compared to existing DMSO-based options, addressing a critical limitation that has hindered iPSC research and therapeutic development. The technology will be commercialized through off-the-shelf products, therapeutic cell type-specific formulations, and custom co-development arrangements with cell and gene therapy companies.